← Leaderboards
Sunil Abraham David
University Of Kansas Lawrence
$6,046,203
Attributed
$6,046,203
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $883.8K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$6,046,203 · 7
By mechanism
U01$4,721,287 · 3
R01$992,217 · 1
R03$216,000 · 2
T32$116,699 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Lipopolysaccharides”
- Bruce A Beutler · Ut Southwestern Medical Center$21,787,231
- Michael Stephen Trent · University Of Georgia$19,970,261
- Daniel E Kahne · Harvard University$19,426,946
- Robert O'Conner · Alion Science And Technology Corp$14,945,723
- Laura E. Nagy · Case Western Reserve University$14,567,506
- Stefanie N. Vogel · University Of Maryland Baltimore$13,942,871
Research focus
LipopolysaccharidesSeptic ShockEndotoxinsCytokineLaboratory MouseClinical ResearchLipid AAnimal ModelCause Of DeathGram-Negative BacteriaGenerationsIn VitroLeadCritical IllnessHigh Throughput ScreeningCategoriesBioterrorismDrug Discovery /IsolationBinding (Molecular Function)Francisella TularensisBrucella Abortus BacteriumBurkholderia MalleiEvaluationImmune Response
Grant awards (24)
Preclinical development of DS-96, a novel alkylpolyamine endotoxin squestrant$308,369
U01 · FY2012 · AI · contact PI
Preclinical development of DS-96, a novel alkylpolyamine endotoxin squestrant$350,129
U01 · FY2011 · AI · contact PI
Preclinical development of DS-96, a novel alkylpolyamine endotoxin squestrant$357,709
U01 · FY2010 · AI · contact PI
Preclinical development of DS-96, a novel alkylpolyamine endotoxin squestrant$365,938
U01 · FY2009 · AI · contact PI
Graduate Training Program in Multidimensional Vaccinogenesis$116,699
T32 · FY2009 · AI · contact PI
Preclinical development of DS-96, a novel alkylpolyamine endotoxin squestrant$35,173
U01 · FY2009 · AI · contact PI
Preclinical development of DS-96, a novel alkylpolyamine endotoxin squestrant$352,724
U01 · FY2008 · AI · contact PI
Gram-Negative Sepsis: Pharmacophore-Based Therapeutics$341,346
U01 · FY2007 · AI · contact PI
Hydrophobic Polyamine Amides as Anti-Endotoxin Agents$264,148
U01 · FY2007 · AI · contact PI
Gram-Negative Sepsis: Pharmacophore-Based Therapeutics$351,540
U01 · FY2006 · AI · contact PI
Hydrophobic Polyamine Amides as Anti-Endotoxin Agents$270,678
U01 · FY2006 · AI · contact PI
Rational Development of Endotoxin Sequestering Agents$246,079
R01 · FY2006 · AI · contact PI
Gram-Negative Sepsis: Pharmacophore-Based Therapeutics$360,000
U01 · FY2005 · AI
Hydrophobic Polyamine Amides as Anti-Endotoxin Agents$271,792
U01 · FY2005 · AI
Rational Development of Endotoxin Sequestering Agents$252,000
R01 · FY2005 · AI
Gram-Negative Sepsis: Pharmacophore-Based Therapeutics$360,000
U01 · FY2004 · AI
Hydrophobic Polyamine Amides as Anti-Endotoxin Agents$267,961
U01 · FY2004 · AI
Rational Development of Endotoxin Sequestering Agents$234,409
R01 · FY2004 · AI
Novel High-throghput Assay:Angiogenesis Inhibitors (RMI)$72,000
R03 · FY2004 · NS
Novel Leads for the Therapy of Gram-Positive Sepsis$72,000
R03 · FY2004 · AI
Hydrophobic Polyamine Amides as Anti-Endotoxin Agents$270,619
U01 · FY2003 · AI
Rational Development of Endotoxin Sequestering Agents$259,729
R01 · FY2003 · AI
Gram-Negative Sepsis: Pharmacophore-Based Therapeutics$193,161
U01 · FY2003 · AI
Novel Leads for the Therapy of Gram-Positive Sepsis$72,000
R03 · FY2003 · AI